Therapeutic Targeting of RAS Mutant Cancers

The KRAS oncogene is a common single nucleotide variant in human cancer, and efforts to target it have struggled. However, recent studies have focused on identifying and exploiting features unique to specific oncogenic mutations, leading to the first FDA approval for a RAS targeted therapy.

Format: Paperback / softback
Length: 75 pages
Publication date: 15 September 2022
Publisher: Cambridge University Press

The KRAS oncogene stands as the most prevalent single nucleotide variant oncogene implicated in human cancer. Throughout history, endeavors to target KRAS and the other RAS GTPases have encountered significant challenges. However, in recent times, there has been a shift in focus towards identifying and harnessing distinctive characteristics specific to individual oncogenic mutations. This transformative approach has culminated in the first FDA approval for a RAS-targeted therapy. This novel agent is a covalent inhibitor that specifically binds to the cysteine residue formed by the codon 12 glycine to cysteine (G12C) mutation within KRAS.

It is worth noting that mutant-specific strategies may also be viable for other KRAS single nucleotide variants, and recent studies have shed light on examples and mechanisms in this regard. The field of cancer research continues to evolve, offering promising avenues for personalized and targeted treatments that hold the potential to improve patient outcomes and revolutionize the field of oncology.

Weight: 67g
ISBN-13: 9781009073646